Recurrent tonsillitis disease (RT) is a common indication for pediatric tonsillectomy, the most frequent childhood surgery. It is unknown why some children develop RT. The present disclosure demonstrates that RT tonsils exhibit significantly smaller germinal centers than non-RT tonsils, concomitant with a bias against Group A Streptococcus (GAS)-specific germinal center follicular helper CD4.sup.+ T cells (GC Tfh), and significantly reduced antibodies to the GAS virulence factor SpeA. The present disclosure also shows a significant immunogenetic component to this disease, with the identification of ‘at risk’ and ‘protective’ HLA alleles for RT. Finally, the present disclosure identifies a new cell type, granzyme B+GC Tfh cells, which are activated by SpeA, are significantly more abundant in RT GC Tfh cells, and have the capacity to kill B cells, thus, providing a window into the immunology and genetics of a classic childhood disease and identifies a new type of pathogenic T cell.

Disclosed herein is a method of providing a metabololipidomic profile and SPM signature on the progress of the innate host defense response following blood clotting. The method can include the step of taking one or more measurements in a patient's blood sample, wherein the sample is obtained during the time-course of clotting or coagulation or following clotting or coagulation, of pro-thrombotic and pro-inflammatory mediators (eicosanoids) and specialized pro-resolving mediators SPMs. From these measurements, a personalized metabololipidomic profile can be obtained. By comparing the measurement to that taken from normal or reference blood, a comparison profile can be developed. The profile comparison profile can then be used to make a medical or therapeutic decision.

Disclosed herein is a method of providing a metabololipidomic profile and SPM signature on the progress of the innate host defense response following blood clotting. The method can include the step of taking one or more measurements in a patient's blood sample, wherein the sample is obtained during the time-course of clotting or coagulation or following clotting or coagulation, of pro-thrombotic and pro-inflammatory mediators (eicosanoids) and specialized pro-resolving mediators SPMs. From these measurements, a personalized metabololipidomic profile can be obtained. By comparing the measurement to that taken from normal or reference blood, a comparison profile can be developed. The profile comparison profile can then be used to make a medical or therapeutic decision.

A replacement fluid suitable to replace a target fluid, wherein the replacement fluid is different from the target fluid. The replacement fluid has pipetting characteristics substantially equivalent to the target fluid, wherein for a desired pipetted volume of the target fluid delivered by a pipette, a pipetted volume of the replacement fluid delivered by the pipette is substantially equivalent to the desired pipetted volume of the target fluid. The replacement fluid is a primary equivalent fluid having substantially similar pipetting characteristics. One or more additives may be added to the primary equivalent fluid. The one or more additives may include pipettability modifying additives and non pipettability modifying additives.

A replacement fluid suitable to replace a target fluid, wherein the replacement fluid is different from the target fluid. The replacement fluid has pipetting characteristics substantially equivalent to the target fluid, wherein for a desired pipetted volume of the target fluid delivered by a pipette, a pipetted volume of the replacement fluid delivered by the pipette is substantially equivalent to the desired pipetted volume of the target fluid. The replacement fluid is a primary equivalent fluid having substantially similar pipetting characteristics. One or more additives may be added to the primary equivalent fluid. The one or more additives may include pipettability modifying additives and non pipettability modifying additives.

In some embodiments, a process and system are provided for generating a user interface for classification of a sample image of a cell that includes receiving a sample image of a sample particle from a biological sample and selecting reference images that each portray a reference particle of a biological sample. The reference images can be ordered based on similarity and the reference images can be selected based on the order. The first selected reference image can be aligned with the sample image and expanded such that the adjacent edges of the reference image and sample image are the same. The expanded image can be dynamically filled. The sample image and the expanded reference image can be displayed in a user interface.

In some embodiments, a process and system are provided for generating a user interface for classification of a sample image of a cell that includes receiving a sample image of a sample particle from a biological sample and selecting reference images that each portray a reference particle of a biological sample. The reference images can be ordered based on similarity and the reference images can be selected based on the order. The first selected reference image can be aligned with the sample image and expanded such that the adjacent edges of the reference image and sample image are the same. The expanded image can be dynamically filled. The sample image and the expanded reference image can be displayed in a user interface.

A blood analyzer according to one or more embodiments may include: a specimen preparation part that prepares a measurement specimen by mixing a reagent into a blood preparation; a measurement part that measures the measurement specimen; a measurement mode selection unit that receives an input of a type of blood preparation as a measurement target selected from a plurality of types of blood preparations; and a controller. The controller may cause the specimen preparation part to prepare the measurement specimen depending on the selected type of blood preparation.

A blood analyzer according to one or more embodiments may include: a specimen preparation part that prepares a measurement specimen by mixing a reagent into a blood preparation; a measurement part that measures the measurement specimen; a measurement mode selection unit that receives an input of a type of blood preparation as a measurement target selected from a plurality of types of blood preparations; and a controller. The controller may cause the specimen preparation part to prepare the measurement specimen depending on the selected type of blood preparation.

The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.